HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


VOC regulation

This article was originally published in The Rose Sheet

Executive Summary

Direct final rule approving revisions to Maryland's state implementation plan establishing VOC content limits for approximately 80 consumer product categories and subcategories will be effective Jan. 23 barring any "adverse written comments" received by Jan. 8, Environmental Protection Agency says in Dec. 9 Federal Register. Rule was submitted to EPA Nov. 19 by Maryland Department of the Environment. Maryland SIP conforms to Ozone Transport Commission model rule developed as a guide for several Northeastern states and includes VOC limits for nail polish remover and aerosol antiperspirant/deodorant (1"The Rose Sheet" April 2, 2001, p. 9). EPA also is proposing to approve New Jersey's SIP revision, which was submitted last January to satisfy the Clean Air Act requirement that stationary sources report their emissions of air pollutants including VOCs to the state each year. The agency will accept comments through Jan. 8...

You may also be interested in...

Ozone Transport Final Draft Sets 75% VOC Limit For Nail Polish Removers

The Ozone Transport Commission's proposed final rule for consumer and commercial products sets volatile organic compound limits for nail polish remover at 75%, well above the 0% limit set by California Air Resources Board standards, on which the reg is modeled.

Beauty Market News: China Cosmetics Regulations Modernized, Florida Stops Local Oxybenzone Bans, More

L’Oreal acquires Thayers Natural Remedies; Unilever, L’Oreal remove ‘whitening,’ ‘fair’ from labels; China finalizes modernization of cosmetics regulations; and Florida governor signs law preventing local bans on oxybenzone.

Compounded Hormone Therapies Lack Evidence Of Safety And Effectiveness, Say National Academies

The US Food and Drug Administration should require that outsourcing facilities collect bioavailability data for compounded bioidentical hormone replacement therapy products, while compounding pharmacies should be required to report adverse events to state pharmacy boards and the FDA. Such actions would help resolve some of the safety concerns for these products, says a 1 July report from the National Academy of Sciences, Engineering and Medicine.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts